
==== Front
BMJ OpenBMJ OpenbmjopenbmjopenBMJ Open2044-6055BMJ Publishing Group BMA House, Tavistock Square, London, WC1H 9JR bmjopen-2019-031909corr110.1136/bmjopen-2019-031909corr1Correction1506Correction: An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature 2019 16 12 2019 16 12 2019 9 12 e031909corr1© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.2019This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.special-featureunlockedaccess-typefree
==== Body
Avenell A, Stewart F, Grey A, et al. An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature. BMJ Open 2019;9:e031909. doi: 10.1136/bmjopen-2019-031909

This article has been corrected since it was first published online. Details of retractions and correspondence relating to some references were inadvertently omitted in the first version; the following references have since been corrected to:

[6]Sato Y, Maruoka H, Oizumi K. Amelioration of hemiplegia-associated osteopenia more than 4 years after stroke by 1 alpha-hydroxyvitamin D3 and calcium supplementation. Stroke 1997;28:736–9. [Retraction in Sato Y, Maruoka H, Oizumi K, et al. Stroke 2019 in press. DOI: 10.1161/01.STR.28.4.736].

[7]Sato Y, Honda Y, Kuno H, et al. Menatetrenone ameliorates osteopenia in disuse-affected limbs of vitamin D- and K-deficient stroke patients. Bone 1998;23:291–6. [Retraction in: Sato Y, Honda Y, Kuno H, et al. Bone 2019;124:167].

[8]Sato Y, Manabe S, Kuno H, et al. Amelioration of osteopenia and hypovitaminosis D by 1alpha- hydroxyvitamin D3 in elderly patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;66:64–8. [Retraction in Sato Y, Manabe S, Kuno H, et al. J Neurol Neurosurg Psychiatry 2018;89:E5].

[9]Sato Y, Honda Y, Kaji M, et al. Amelioration of osteoporosis by menatetrenone in elderly female Parkinson's disease patients with vitamin D deficiency. Bone 2002;31:114–8. [Retraction in: Sato Y, Honda Y, Kaji M, et al. Bone 2018;106:212].

[10]Sato Y, Kanoko T, Satoh K, et al. Menatetrenone and vitamin D2 with calcium supplements prevent nonvertebral fracture in elderly women with Alzheimer's disease. Bone 2005;36:61–8. [Retraction in: Sato Y, Kanoko T, Satoh K, et al. Bone 2018;106:213].

[11]Sato Y, Iwamoto J, Kanoko T, et al. Risedronate therapy for prevention of hip fracture after stroke in elderly women. Neurology 2005;64:811–6. [Retraction in Sato Y, Iwamoto J, Kanoko T, et al. Neurology 2016;87:239].

[12]Sato Y, Iwamoto J, Kanoko T, et al. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med 2005;165:1743–8. [Retraction in: Sato Y, Iwamoto J, Kanoko T, et al. JAMA Intern Med 2016;176:1256].

[13]Sato Y, Kanoko T, Satoh K, et al. The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial. Arch Intern Med 2005;165:1737–42. [Retraction in: Sato Y, Kanoko T, Satoh K, et al. JAMA Intern Med 2016;176:1256].

[14]Sato Y, Honda Y, Iwamoto J, et al. Effect of folate and mecobalamin on hip fractures in patients with stroke: a randomized controlled trial. JAMA 2005;293:1082–8. [Retraction in: Sato Y, Honda Y, Iwamoto J, et al. JAMA 2016;315:2405].

[15]Sato Y, Iwamoto J, Kanoko T, et al. Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial. Mov Disord 2006;21:924–9. [Retraction in: Sato Y, Iwamoto J, Kanoko T, et al. Mov Disord;31:1077].

[16]Sato Y, Honda Y, Iwamoto J. Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. Neurology 2007;68:911–5. [Retraction in: Sato Y, Honda Y, Iwamoto J. Neurology 2016;87:239].

[17]Sato Y, Iwamoto J, Honda Y. Once-weekly risedronate for prevention of hip fracture in women with Parkinson's disease: a randomised controlled trial. J Neurol Neurosurg Psychiatry 2011;82:1390-3. [Retraction in: Sato Y, Iwamoto, Honda Y. J Neurol Neurosurg Psychiatry 2018;89:E4].

[85]Clarke CE. Efficacy of methyprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2004;75:510–11; author reply 511.

[86]Poole KE, Warburton EA, Reeve J. Risedronate therapy for prevention of hip fracture after stroke in elderly women. Neurology 2005;65:1513–14; author reply 1513–4.

[87]Caffrey N, Casey M, Walsh B. Substandard studies or substandard “standard-of-care.” J Bone Miner Res 2006; 21:491; author reply 492.

[88]Halbekath JM, Schenk S, von Maxen A, et al. Risedronate for the prevention of hip fractures: concern about validity of trials. Arch Intern Med 2007;167:513–14; author reply 514–515.

